RxDoctor Payments Data

Michael Naguit, MD

Psychiatry · Clairton, PANPI 1952542128

Payments from drug & device makers

$5,103in general payments, 2019–2025

Across 265 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lundbeck LLC$536
  • Neurocrine Biosciences, Inc.$392
  • Teva Pharmaceuticals USA, Inc.$375
  • Johnson & Johnson$260
  • Takeda Pharmaceuticals U.S.A., Inc.$247
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,99298%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,103 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,969
Medicare patients
66
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$165,431
NuplazidPimavanserin Tartrate12$52,296
TrintellixVortioxetine Hydrobromide35$26,525
Clonazepam467$4,290
Venlafaxine Hcl ErVenlafaxine Hcl220$3,950
Duloxetine Hcl296$3,864
Fluvoxamine Maleate43$3,651
Bupropion Hcl SrBupropion Hcl149$3,544
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine110$3,492
Doxepin Hcl29$3,070
Quetiapine Fumarate131$2,667
Bupropion XlBupropion Hcl94$2,573
Divalproex Sodium24$2,525
Sertraline Hcl191$2,099
Buspirone Hcl119$1,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$375$165,43113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$247$26,52535 claims
Almatica Pharma LLCSertraline Hcl$204$2,099191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Clairton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →